{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:30:00Z","timestamp":1786973400984,"version":"build-2736575974"},"reference-count":37,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>To determine the effects of the comprehensive disease-modifying pharmacological approach among patients with heart failure with reduced ejection fraction, a cross-trial, aggregate-data analysis was performed to estimate the expected combined effect of quintuple therapy by multiplying trial-level HRs, assuming independent and multiplicative treatment effects from Phase III randomised clinical trials: EMPHASIS-HF, PARADIGM-HF, pooled DAPA-HF and EMPEROR-Reduced, and pooled VICTORIA and VICTOR. The imputed aggregate treatment effects on the primary endpoint of cardiovascular death or first heart failure hospitalisation were favourable to the quintuple compared with conventional therapy (HR 0.34; 95% CI [0.27\u20130.42]). This also occurred for cardiovascular death alone (HR 0.47; 95% CI [0.35\u20130.63]), first heart failure hospitalisation (HR 0.31; 95% CI [0.23\u20130.40]) and all-cause mortality (HR 0.51; 95% CI [0.39\u20130.67]). The numbers needed to treat per year for the primary outcome, cardiovascular death and first heart failure hospitalisation were 10, 23 and 15, respectively. Our findings support the potential benefit of comprehensive therapy, with the incremental role of vericiguat likely greatest in higher-risk patients or those with recent worsening heart failure.<\/jats:p>","DOI":"10.15420\/cfr.2026.02","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:38:17Z","timestamp":1786199897000},"source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-4735","authenticated-orcid":false,"given":"Carlos","family":"Escobar","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-8371","authenticated-orcid":false,"given":"Pedro","family":"Caravaca-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-1835","authenticated-orcid":false,"given":"Jos\u00e9 Maria","family":"Fernandez-Rodriguez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v85ar63","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario Central de Asturias"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-2464","authenticated-orcid":false,"given":"Ines","family":"Gomez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-4116","authenticated-orcid":false,"given":"Ainara","family":"Lozano-Bahamonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-4263","authenticated-orcid":false,"given":"Alejandro I","family":"P\u00e9rez-Cabeza","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xxs2z38","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednico Universitario Virgen de la Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-5896","authenticated-orcid":false,"given":"Jos\u00e9","family":"P\u00e9rez-Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-6045","authenticated-orcid":false,"given":"Carles","family":"Rafols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-4654","authenticated-orcid":false,"given":"Jes\u00fas","family":"Salda\u00f1a-Garc\u00eda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-7336","authenticated-orcid":false,"given":"Alberto","family":"Esteban-Fern\u00e1ndez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05s3h8004","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario Severo Ochoa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref0","unstructured":"Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 2025;151:e41\u2013660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303; PMID: 39866113."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013; PMID: 35150240. DOI: 10.1093\/cvr\/cvac013","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail 2023;29:1412\u201351. https:\/\/doi.org\/10.1016\/j.cardfail.2023.07.006; PMID: 37797885. DOI: 10.1016\/j.cardfail.2023.07.006","DOI":"10.1016\/j.cardfail.2023.07.006"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Jones NR, Roalfe AK, Adoki I, et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 2019;21:1306\u201325. https:\/\/doi.org\/10.1002\/ejhf.1594; PMID: 31523902. DOI: 10.1002\/ejhf.1594","DOI":"10.1002\/ejhf.1594"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Esteban-Fern\u00e1ndez A, Anguita-S\u00e1nchez M, Anguita-G\u00e1mez M, et al. 30-day readmissions for circulatory system diseases in patients over 75 years with heart failure in Spain (2016\u20132018). Rev Esp Cardiol (Engl Ed) 2023;76:655\u20136. https:\/\/doi.org\/10.1016\/j.rec.2023.02.017; PMID: 37137425. DOI: 10.1016\/j.rec.2023.02.017","DOI":"10.1016\/j.rec.2023.02.017"},{"key":"ref5","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128; PMID: 27206819."},{"key":"ref6","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID: 34447992."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492; PMID: 21073363. DOI: 10.1056\/NEJMoa1009492","DOI":"10.1056\/NEJMoa1009492"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077; PMID: 25176015. DOI: 10.1056\/NEJMoa1409077","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref9","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303; PMID: 31535829."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 2020;396:121\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30748-0; PMID: 32446323. DOI: 10.1016\/S0140-6736(20)30748-0","DOI":"10.1016\/S0140-6736(20)30748-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J 2020;41:2379\u201392. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa183; PMID: 32221582. DOI: 10.1093\/eurheartj\/ehaa183","DOI":"10.1093\/eurheartj\/ehaa183"},{"key":"ref12","unstructured":"Esteban-Fern\u00e1ndez A, G\u00f3mez-Otero I, L\u00f3pez-Fern\u00e1ndez S, et al. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction. Clin Res Cardiol 2024;113:1171\u201382. https:\/\/doi.org\/10.1007\/s00392-023-02241-0; PMID: 37341769."},{"key":"ref13","unstructured":"Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070; PMID: 30025570."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ruppar TM, Cooper PS, Mehr DR, et al. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc 2016;5:e002606. https:\/\/doi.org\/10.1161\/JAHA.115.002606; PMID: 27317347. DOI: 10.1161\/JAHA.115.002606","DOI":"10.1161\/JAHA.115.002606"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928; PMID: 32222134. DOI: 10.1056\/NEJMoa1915928","DOI":"10.1056\/NEJMoa1915928"},{"key":"ref16","unstructured":"Butler J, McMullan CJ, Anstrom KJ, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2025;406:1341\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(25)01665-4; PMID: 40897189."},{"key":"ref17","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190; PMID: 32865377."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9; PMID: 32877652. DOI: 10.1016\/S0140-6736(20)31824-9","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"ref19","unstructured":"Zannad F, O\u2019Connor CM, Butler J, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025;406:1351\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(25)01682-4; PMID: 40897188."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Docherty KF, Stienen S, et al. Estimating the lifetime benefits of treatments for heart failure. JACC Heart Fail 2020;8:984\u201395. https:\/\/doi.org\/10.1016\/j.jchf.2020.08.004; PMID: 33039448. DOI: 10.1016\/j.jchf.2020.08.004","DOI":"10.1016\/j.jchf.2020.08.004"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail 2017;10:e003529. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003529; PMID: 28087688. DOI: 10.1161\/CIRCHEARTFAILURE.116.003529","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Gupta SD, Butt JH, McMurray EGM, et al. Effects of sacubitril\/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF. Eur J Heart Fail 2025;27:779\u201387. https:\/\/doi.org\/10.1002\/ejhf.3515; PMID: 39563094. DOI: 10.1002\/ejhf.3515","DOI":"10.1002\/ejhf.3515"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril\/valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy. Circ Heart Failure 2016;9:e003212. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003212; PMID: 27618854. DOI: 10.1161\/CIRCHEARTFAILURE.116.003212","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagliflozin in patients with HFrEF treated with Sacubitril\/Valsartan: the DAPA-HF trial. JACC Heart Fail 2020;8:811\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.008; PMID: 32653447. DOI: 10.1016\/j.jchf.2020.04.008","DOI":"10.1016\/j.jchf.2020.04.008"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ezekowitz JA, McMullan CJ, Westerhout CM, et al. Background medical therapy and clinical outcomes from the VICTORIA trial. Circ Heart Fail 2023;16:e010599. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010599; PMID: 37417824. DOI: 10.1161\/CIRCHEARTFAILURE.123.010599","DOI":"10.1161\/CIRCHEARTFAILURE.123.010599"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail 2022;10:73\u201384. https:\/\/doi.org\/10.1016\/j.jchf.2021.09.004; PMID: 34895860. DOI: 10.1016\/j.jchf.2021.09.004","DOI":"10.1016\/j.jchf.2021.09.004"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Khullar D, Gupta AK, Singh K. Finerenone: will it be a game-changer? Card Fail Rev 2024;10:e19. https:\/\/doi.org\/10.15420\/cfr.2024.11; PMID: 39872849. DOI: 10.15420\/cfr.2024.11","DOI":"10.15420\/cfr.2024.11"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Escobar C, Luis-Bonilla J, Crespo-Leiro MG, et al. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. Expert Opin Pharmacother 2022;23:1589\u201399. https:\/\/doi.org\/10.1080\/14656566.2022.2116275; PMID: 35995759. DOI: 10.1080\/14656566.2022.2116275","DOI":"10.1080\/14656566.2022.2116275"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Esteban Fern\u00e1ndez A, Recio Mayoral A, Gonz\u00e1lez Franco A, et al. Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization. Expert Opin Pharmacother 2023;24:705\u201313. https:\/\/doi.org\/10.1080\/14656566.2023.2195540; PMID: 36961877. DOI: 10.1080\/14656566.2023.2195540","DOI":"10.1080\/14656566.2023.2195540"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Escobar Cervantes C, Esteban Fern\u00e1ndez A, Recio Mayoral A, et al. Identifying the patient with heart failure to be treated with vericiguat. Curr Med Res Opin 2023;39:661\u20139. https:\/\/doi.org\/10.1080\/03007995.2023.2189857; PMID: 36897009. DOI: 10.1080\/03007995.2023.2189857","DOI":"10.1080\/03007995.2023.2189857"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kristensen SL, Docherty KF, Jhund PS, et al. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. Eur Heart J 2020;41(Suppl 2):ehaa946.0939. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.0939. DOI: 10.1093\/ehjci\/ehaa946.0939","DOI":"10.1093\/ehjci\/ehaa946.0939"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Carrizales-Sep\u00falveda EF, Ordaz-Far\u00edas A, Vargas-Mendoza JA, et al. Initiation and up-titration of guideline-directed medical therapy for patients with heart failure: better, faster, stronger! Card Fail Rev 2024;10:e03. https:\/\/doi.org\/10.15420\/cfr.2023.20; PMID: 38533397. DOI: 10.15420\/cfr.2023.20","DOI":"10.15420\/cfr.2023.20"},{"key":"ref33","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, et al. Management of worsening heart failure with reduced ejection fraction: JACC focus Seminar 3\/3. J Am Coll Cardiol 2023;82:559\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.057; PMID: 37532426."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2024;83:1444\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.024; PMID: 38466244. DOI: 10.1016\/j.jacc.2023.12.024","DOI":"10.1016\/j.jacc.2023.12.024"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Writing Committee, Hollenberg SM, Stevenson LW, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2024;84:1241\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.002; PMID: 39127954. DOI: 10.1016\/j.jacc.2024.06.002","DOI":"10.1016\/j.jacc.2024.06.002"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kerwagen F, Ohlmeier C, Evers T, et al. Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany. Eur J Clin Pharmacol 2024;80:931\u201340. https:\/\/doi.org\/10.1007\/s00228-024-03654-0; PMID: 38472389. DOI: 10.1007\/s00228-024-03654-0","DOI":"10.1007\/s00228-024-03654-0"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.02","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:14:53Z","timestamp":1786972493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2026.02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":37,"URL":"https:\/\/doi.org\/10.15420\/cfr.2026.02","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"e22"}}